Updated time: 2022-10-21 09:27:42
28A-1060810
TW I728272、US 11434277 B2
Pandemic and epidemic outbreaks of influenza A virus (IAV) infection pose severe challenges to human society. Passive immunotherapy with recombinant neutralizing antibodies can potentially mitigate the threats of IAV infection. With a high throughput neutralizing antibody discovery platform, we produced artificial anti-hemagglutinin (HA) IAV-neutralizing IgGs from phage-displayed synthetic scFv libraries without necessitating prior memory of antibody-antigen interactions or relying on affinity maturation essential for in vivo immune systems to generate highly specific neutralizing antibodies. At least two thirds of the epitope groups of the artificial anti-HA antibodies resemble those of natural protective anti-HA antibodies, providing alternatives to neutralizing antibodies from natural antibody repertoires.
GH2 antibody libraries with diverse CDR-H3 sequence lengths can discovery neutralizing antibodies against IAV infection, providing passive immunotherapy antibodies as alternatives to neutralizing antibodies derived from natural antibody repertoires.
Vaccine development
An-Suei Yang, Ing-Chien Chen, Yi-Kai Chiu, Chung-Ming Yu, Cheng-Chung Lee, Chao-Ping Tung, Yueh-Liang Tsou, Yi-Jen Huang, Chia-Lung Lin, Hong-Sen Chen, Hwei-Jiung Wang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries